



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)

(於中華人民共和國註冊成立的股份有限公司)

(Stock code 股份代號 : 9989)

NOTIFICATION LETTER 通知信函

Dear Registered Shareholder (N.1),

December 18, 2023

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "Company")

- Notice of publication of Circular, Notice and Proxy Form of the 2024 First Extraordinary General Meeting (the "Current Corporate Communications")

The Board of Directors of the Company has decided to convene a shareholders' general meeting on _____ at the HKE (the "Meeting"). You are invited to attend the Meeting and exercise your voting rights. If you are unable to attend the Meeting in person, you may appoint a proxy to attend on your behalf.

If you wish to exercise your voting rights at the Meeting, you must complete the Request Form (the "Request Form") (which can be downloaded from the back of the Circular, the Company's (or its) Electronic Service List (the "Hong Kong Share Registrar") website, or by email to the Request Form (located in Hong Kong). One copy of the Request Form should be sent to the Hong Kong Share Registrar, 17/F, Finance Centre, 16 Harbour Road, Hong Kong.

Unless otherwise specified, the Request Form should be completed in accordance with the following instructions.

Should you have any questions, please contact the Hong Kong Share Registrar (852) 2980 1333 from 9:00 am to 6:00 pm, Monday to Friday, excluding public holidays.

Yours faithfully,
Fadbe aff
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

N.1: The registered shareholder(s) of the Company who are entitled to attend and vote at the Meeting. (CCASS) and the Hong Kong Share Registrar. The Company's Electronic Service List (the "Hong Kong Share Registrar") website. If you are unable to attend the Meeting in person, you may appoint a proxy to attend on your behalf.

N.2: The Company's "Corporate Communications" (the "Request Form") (which can be downloaded from the back of the Circular, the Company's (or its) Electronic Service List (the "Hong Kong Share Registrar") website, or by email to the Request Form (located in Hong Kong). One copy of the Request Form should be sent to the Hong Kong Share Registrar, 17/F, Finance Centre, 16 Harbour Road, Hong Kong.

致非登記股份持有人(附註1):

深圳市海普瑞藥業集團股份有限公司(「本公司」)
- 2024年第一次臨時股東大會通函、通告及代表委任表格(「本次公司通訊文件」)之發佈通知

本公司的本次公司通訊文件中、英文版本現已上載於本公司網站_____及香港交易所披露易網站_____, 歡迎瀏覽。請在本公司網站主頁的「投資者專區」項下選擇有關文件或在香港交易所披露易網站瀏覽有關文件。

如閣下欲收取本公司本次及將來所有公司通訊文件(附註2)之印刷本, 請填妥在本信函背面的申請表格(「申請表格」)(該表格亦可於上述網站下載), 並使用申請表格下方的預付費郵寄標籤寄回(如在香港投寄); 否則, 請貼上足夠的郵票。申請表格請經卓佳證券登記有限公司(「香港股份登記處」)寄回本公司, 香港股份登記處的地址為香港夏慤道16號遠東金融中心17樓。

謹

希望收到本公司公司通訊文件。如果閣下已出售或轉讓全部所持有的本公司股份, 則無需要理會本信函及其背面的申請表格。

附註2: 本公司公司通訊文件(「公司通訊文件」)指本公司發出或將予發出以供其任何證券的持有人參照或採取行動的任何文件, 其中包括但不限於: (a) 年度報告及財務摘要報告(如適用); (b) 中期報告及中期摘要報告(如適用); (c) 會議通告; (d) 上市文件; (e) 通函; 及(f) 委任代表表格。

